Short answer
IDEAYA Biosciences, Inc. (IDYA) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $9M with net income of −$112M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- +35.0% QoQ
- Net income
- −$112M
- −45.1% YoY · −14.1% QoQ
- Operating margin
- -1380.7%
- EPS (diluted)
- −$1.22
- −40.2% YoY · −9.9% QoQ
Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) Q2 2026 10-Q on SEC EDGAR. USD.
IDEAYA Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $8.9M in Q2 2026; no Q2 2025 comparison provided
- Net loss $112.5M in Q2; R&D expense $108.7M, up 14% sequentially
- Darovasertib largest clinical investment at $32.1M; IDE161 lowest at $2.0M
- Cash, equivalents and marketable securities $1.24B at June 30; follow-on offering net proceeds $323.4M
- NDA submission planned second half 2026; losses expected to increase with development and regulatory activities
Risk Factors
- No new, changed, regulatory, operational, competitive, or financial risks identifiable from Items 2–6
- June 2026 pre-funded warrant form filed as Exhibit 4.7
- No unregistered equity sales or issuer share repurchases during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IDEAYA Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.